Clinical research - Today Stories

Global investigative sites recognize Parexel’s commitment to strong site relationships and patients DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2024 Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category for the second consecutive year. This prestigious award, presented at the annual SCRS Global Site Solutions Summit held Sept. 27-29 in Hollywood, Fla., underscores Parexel’s dedication to fostering strong partnerships with investigative sites and advancing patient-guided clinical research. "This recognition reaffirms our commitment to collaborating with sites, which is crucial for…

A multi-million-pound clinical trial to find out whether existing drugs could be used to treat people with a debilitating lung disease called Bronchiectasis will start next month. Despite being the third most common lung condition in the UK, bronchiectasis is sometimes considered to be a ‘hidden’ disease due to a lack of public awareness, investment and research. The disease occurs when tubes in the lungs, called bronchi, become permanently damaged and widened, resulting in persistent breathing difficulties and repeated lung infections. The condition affects 1 in 200 people in the UK (approximately 200,000) but numbers are increasing due to an aging population. In the past decade, cases have increased by 40% and they are expected to grow globally by a further 20% over the next 10 years. De…

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Advanced eClinical Training (ACT) is proud to announce its top ranking on Forbes Education's prestigious Best CMA Certification Online list for 2024. This recognition is a testament to the institution's unwavering commitment to providing superior education and training for future healthcare professionals. Forbes Education's annual ranking evaluates online Certified Medical Assistant (CMA) programs based on a comprehensive set of criteria including program quality, faculty expertise, student outcomes, and overall value. Advanced eClinical Training has been recognized for its exceptional dedication to excellence in these areas, setting a benchmark for online healthcare education. Key Reasons for Selection: 1. Comprehensive Curriculum:Advanced eCl…

Boehringer Ingelheim and Gubra today announced the launch of the Phase 1 study (NCT06352437) of BI 3034701, a long-acting triple agonist peptide with a potential to become a next-generation and first-in-class obesity treatment.  More than 1 billion people worldwide live with obesity, and numbers are continuing to rise. Estimations show that by 2035, 24% of the entire world population will be affected by this disease.1 Obesity is a major risk factor for other cardiovascular, renal, and metabolic (CRM) diseases as well as for several types of cancer, which collectively are a leading cause of death worldwide. With the progression of BI 3034701, Boehringer Ingelheim further expands its pipeline of patient-centric solutions beyond weight loss for people living with obesity to achieve CRM he…

The PPD clinical research business will nearly double its laboratory footprint in northern Kentucky, add more than 250 jobs WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today announced the expansion of its central laboratory operations in Kentucky dedicated to accelerating pharmaceutical and biotech customers’ delivery of safe, effective medicines to patients. The business will expand its sample management and biorepository operations in a new 65,000-square-foot space in Covington, enabling further capability expansion at its existing site in nearby Highland Heights. Thermo Fisher’s $47.8 million investment is expected to create more than 250 new jobs across the two sites over the next eight ye…

The PPD clinical research business' new laboratory will enhance services in new and emerging therapeutic areas, add 350 new jobs to region WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. The new 72,500-square-foot building increases the site’s chemistry, manufacturing and control (CMC) analytical capabilities as part of its clinical development and laboratory services focused on improving health by helping customers deliver life-changing medicines. “As research in biopharmaceutical therapies continues to rapidly expand, we are excited to expand our overall capacity and…

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites. "The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investigator workflow, improves the patient experience and ultimately enables biopharma sponsors to bring therapies to market faster," said Jon DiVincen…

7 May 2024 UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets. Gentronix recorded total growth of 239% in overseas earnings over the past three years, with the percentage of total sales exported rising from 71% to 81% over the same period, driving revenue to in excess of £10m per annum. The US has been a particularly strong area of growth and this market now makes up almost half of the firm’s international business, with demand continuing to increase across North America. As a result of the business’s success and enhanced overseas trading, Gentronix has received a prestigious K…

Company recognized by a distinguished industry advisory board for its expertise and leadership in supporting the development of vaccines DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been named “Best Contract Research Organization” at the 17th Annual Vaccine Industry Excellence (ViE) Awards. Winners were named across 13 categories, including Best Contract Research Organization, which recognizes the role of CROs in supporting the development of safe and effective vaccines. “We are honored to be recognized with this year’s ViE Award for Best Contract Research Organization,” said Amy McKee, MD, Chief Medical Officer &…

PPD clinical research business provides lab customers a comprehensive solution to help ensure safe medicines for patients WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is adding mycoplasma and additional biosafety testing capabilities to its expanding portfolio of services at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. This new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for patients. “The continuing expansion of our GMP lab to include these new services further strengthens our ability to help our customers make the world healthie…

Dublin, Ireland – 24 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent industry survey of over 100 professionals engaged in obesity-related clinical research to measure industry opinions on trends within this therapeutic area. The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome. There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with this, most respondents (64%) felt combination therapies would be the primary focus of future research. Furthermore, half of respondents are employing multi-indication studies…

Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has heralded the start of its next successful phase with four promotions and eight new arrivals. Dr Shailendra Singh, CEO of Cellomatics Biosciences, comments: “Capitalising on our existing strengths and internal team expertise, we intend to further consolidate our position as a specialist biology CRO by broadening and deepening our service offerings in 2024. With these new appointments and internal restructuring, we are poised to catapult ourselves to the next phase of our growth journey.” Cellomatics is building on its expanding client base which now boasts over a hundred global clients, delivering approximately 320 scientific projects across all therapeutic areas of which sixty-six projects were complete…

Survey points to importance of strategic engagement with investors and effective asset development strategies to optimise funding Dublin, Ireland – 8 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding. A recent survey of over 130 biotech executives, published by ICON, shows that 60% of respondents expected to increase R&D spending, whilst only 2% planned to reduce funding. While respondents were confident in their outlook with regards to investment milestones and product su…

Healthcare intelligence organisation earns recognition as employer of choice and leading innovator in the clinical trial industry Dublin, Ireland – 18 December 2023 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation.  In recognition of its Environmental, Social and Governance (ESG) efforts and as an employer of choice, ICON ranked 88th in TIME’s list of the World’s Best Companies of 2023, the highest ranking CRO within the top 750 companies included. The award evaluates companies using standardised KPIs on sustainability, revenue and employee satisfaction. ICON was also included on both the Forbes World’s Best E…

Almac Discovery and Queen’s University Belfast have today announced a five-year project to develop a new Chemoproteomics Centre of Excellence for drug discovery.The multi-million-pound facility, which is jointly funded by Almac Discovery and a BBSRC Prosperity Partnership award, is a first of its kind in Northern Ireland and will be located at Queen’s.The project combines and harnesses the experience of industrial and academic experts to shine a new light on the way drug molecules could be used to treat disease, by using advanced mass spectrometry techniques to examine their effects on thousands of potential drug targets simultaneously, in disease relevant systems.This latest collaboration builds on a long-established relationship between Almac Discovery and Queen’s in biological research…

Prestigious industry recognition reflects company’s commitment to the development of strong site relationships in support of patients DURHAM, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2023 Society for Clinical Research Sites (SCRS) Eagle Award (CRO category). Parexel received the award at the annual Global Site Solutions Summit held Oct. 6-8 in Hollywood, Fla. The SCRS Eagle Award recognizes the sponsor and CRO committed to outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships. “Parexel’s collaboration with s…

Solution seamlessly delivers proprietary technology, real world data and analytics, aligning to industry security and data privacy standards Dublin, Ireland – 20 September 2023 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON’s proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle. ICON’s next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to…

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, today announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC). The collaboration supports biopharmaceutical and biotech customers in meeting regulatory expectations to enroll and retain patients in clinical trials who more fully reflect real-world populations experiencing the disease or health condition being studied, including U.S. Food and Drug Administration requirements around diversity action plans. The work reflects Thermo Fisher and NMQF’s share…

Caidya was honored at the CRO Leadership Awards held in Boston, MA at the end of June for their win in the Overall Capabilities category. The award is a recognition of Caidya’s outstanding global capabilities and the tireless work that the team does daily to fulfill our vision to ensure potential therapies have the best opportunity to reach patients in need. Vice President of Business Development (China), Jinye Shen, attended on behalf of Caidya and expressed her gratitude and excitement for the award in a brief interview with the hosting president, Krishnan Rajugopalan. Key points she raised are: Caidya operates with an ownership mentality towards clinical research, making our clients’ success a measure of our own success. As a global company, we help clients navigate regulatory complexi…

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the discovery of its lead clinical candidate, STC-15, which is an orally bioavailable and highly selective METTL3 inhibitor, at the American Chemical Society (ACS) Fall 2023 Conference, in San Francisco, California on the 13-17 August 2023. The presentation entitled “Discovery of STC-15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development” will detail the Company’s discovery effor…